-+ 0.00%
-+ 0.00%
-+ 0.00%

Neurogene highlights NGN-401 Phase 1/2 Rett syndrome data ahead of ASGCT poster

PUBT·04/28/2026 11:36:21
Listen to the news
Neurogene highlights NGN-401 Phase 1/2 Rett syndrome data ahead of ASGCT poster
  • Neurogene announced a poster presentation at ASGCT Annual Meeting on May 12, 2026, outlining rationale for intracerebroventricular delivery in CNS-targeted gene therapy.
  • Presentation will highlight preclinical findings supporting broader brain and nervous system distribution for NGN-401 in Rett syndrome versus intrathecal-lumbar delivery.
  • Poster will also review clinical observations indicating tolerability for ICV administration, with safety driven primarily by product profile rather than delivery route.
  • Neurogene pointed to ongoing Phase 1/2 NGN-401 trial showing durable, multidomain developmental milestone gains over time, supporting continued advancement into Embolden registrational study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604280730BIZWIRE_USPR_____20260428_BW694916) on April 28, 2026, and is solely responsible for the information contained therein.